Omniox Inc., Cary’s young San Francisco company, is testing oxygen-binding proteins as treatments for aggressive cancers, heart attacks, strokes and battlefield wounds. It is the proverbial “multiple shots on goal” that is the aim of biotech company executives: You can miss wide with several indications, the thinking goes, as long as you score big with one.
The range of possibilities could be a boon for Omniox as it chats up potential venture backers, especially if proof-of-concept brain cancer and heart attack studies in animals over the next six months prove that the company is more than an extended research project.
No comments:
Post a Comment